急性骨髓性白血病,动物模型 z-bio 2021-06-09 388

　　New research shows that nanoparticles carrying miR-22, a small non-coding NA molecule that can regulate gene expression, have therapeutic potential in mouse models of acute myeloid leukemia. Related results were recently published in "Nature Communications".

　　Acute myeloid leukemia is a type of blood cell cancer that usually causes death within 5 years of intensive chemotherapy. Although there is a lot of information about the characteristics of mutations in the genome of acute myeloid leukemia, little is known about the molecular mechanisms that drive the transformation of progenitor cells into cancer.

　　Chen Jianjun's team from the University of Cincinnati in the United States analyzed the cancer samples of 62 patients and found that the expression of miR-22 in patients with acute myeloid leukemia was reduced. Studies using simple mouse models have shown that inhibition of specific cell conduction pathways restores miR-22 expression, prevents the development of acute myeloid leukemia and the maintenance of cancer cells. The researchers then used nanoparticles to deliver short-chain miR-22NA to two mouse models of leukemia and evaluated the efficacy of miR-22 treatment. In both models, treatment with miR-22 slowed cancer progression and prolonged survival.

　　However, the researchers pointed out that the clinical trials of miR-22-carrying nanoparticles for the treatment of acute myeloid leukemia require further testing, and that the combination with standard chemotherapy drugs can effectively treat acute myeloid leukemia.